C1QTNF7

C1QTNF7 (CTRP7) is a secreted glycoprotein that acts as a pro-metabolic and pro-vascular-remodeling stress factor, contributing to obesity-linked metabolic dysfunction and pulmonary vascular disease (PMID:28223291, PMID:40504501). It assembles into homotrimers as its basic structural unit and can form heterotrimers with CTRP2, providing a route to generate distinct secreted ligands (PMID:18783346). In a high-fat-diet mouse model, genetic deletion of CTRP7 attenuates insulin resistance, reduces adipose inflammation, and lowers hepatic fibrosis and ER/oxidative stress, establishing the protein as a driver of metabolic dysfunction (PMID:28223291); consistent with this, hepatocyte overexpression promotes oxidative stress and suppresses insulin signaling phosphorylation (PMID:35368863). In the vasculature, CTRP7 functions downstream of BK channels in an axis where its loss activates PI3K/Akt signaling governing vascular remodeling (PMID:36514218). In pulmonary artery smooth muscle cells, IL-6 transcriptionally upregulates CTRP7, which then reduces surface PTGIR (prostacyclin receptor) through Rab5a-mediated internalization, blunting responsiveness to the prostacyclin analogue selexipag; AAV-mediated silencing of CTRP7 in hypoxic pulmonary hypertension mice restores PTGIR levels and drug response (PMID:40504501).

1. 2008 Medium

   Establishing CTRP7's biochemical nature as a secreted oligomeric protein defined the structural form in which it could act as a ligand and revealed combinatorial heterotrimer assembly with CTRP2.

   Evidence Mammalian cell expression and biochemical characterization of secreted oligomeric states, with co-expression and co-IP/secretion assays

   PMID:18783346

   Open questions at the time

   • No receptor or downstream effector identified at this stage
   • Functional consequence of CTRP2/CTRP7 heterotrimers versus homotrimers not resolved
   • No tissue-level or physiological role established
2. 2017 High

   A loss-of-function mouse model answered whether CTRP7 contributes to disease physiology, establishing it as a driver of obesity-linked insulin resistance, adipose inflammation, and hepatic stress.

   Evidence Ctrp7 knockout mice on high-fat diet with glucose/insulin tolerance tests, adipose inflammation markers, and liver fibrosis/ER stress assays

   PMID:28223291

   Open questions at the time

   • Molecular mechanism connecting CTRP7 to insulin signaling not defined in this study
   • Receptor mediating metabolic effects unknown
   • Cell-autonomous versus systemic contributions not separated
3. 2022 Medium

   Hepatocyte overexpression provided a cell-level mechanism, linking CTRP7 to oxidative stress and suppression of insulin signaling phosphorylation, consistent with the knockout metabolic phenotype.

   Evidence In vitro hepatocyte overexpression with oxidative stress markers (ROS, SOD, GSH, MDA) and western blotting of insulin signaling phosphorylation

   PMID:35368863

   Open questions at the time

   • Receptor or signaling entry point through which CTRP7 acts not identified
   • Single lab in vitro overexpression, not reconciled with secreted-ligand biology
   • Direction of causality between oxidative stress and insulin signaling not dissected
4. 2022 Medium

   Transcriptomic and knockdown work placed CTRP7 in a vascular signaling axis, showing it lies downstream of BK channels and restrains PI3K/Akt-driven remodeling.

   Evidence RNA-seq of BK channel α-subunit knockout rat aortas, qPCR, siRNA knockdown in human umbilical artery smooth muscle cells, and PI3K/Akt western blotting

   PMID:36514218

   Open questions at the time

   • Mechanism by which BK channels regulate CTRP7 levels unknown
   • How secreted CTRP7 suppresses PI3K/Akt mechanistically not defined
   • In vivo vascular phenotype of CTRP7 perturbation not tested here
5. 2025 High

   A multi-method study resolved a defined signaling cascade, showing IL-6 transcriptionally induces CTRP7, which drives Rab5a-mediated internalization of PTGIR and reduces prostacyclin-analogue responsiveness in pulmonary hypertension.

   Evidence ChIP for IL-6 at the CTRP7 promoter in PASMCs, Rab5a-mediated receptor internalization assay, in vivo AAV silencing and IL-6R antibody treatment in hypoxic PH mice with hemodynamic readouts

   PMID:40504501

   Open questions at the time

   • Direct receptor through which secreted CTRP7 triggers Rab5a-mediated PTGIR internalization not identified
   • Whether the same IL-6→CTRP7→PTGIR axis operates in the metabolic tissues is untested
   • Structural basis of CTRP7 action remains uncharacterized

• The cell-surface receptor(s) and direct molecular effectors that transduce secreted CTRP7 signaling across metabolic and vascular contexts remain unidentified.
• No receptor mediating CTRP7's metabolic or vascular effects identified
• No structural model of CTRP7 trimers or heterotrimers
• Unifying mechanism across liver, adipose, and pulmonary vasculature not established